Focus: Rivus Pharmaceuticals is a public-stage biotech focused on Controlled Metabolic Accelerators for neurology and metabolic diseases, headquartered in Charlottesville, VA. The company combines legacy generic assets with an early-stage pipeline targeting high-prevalence metabolic indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Rivus Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-LOE generic opioid asset; likely legacy revenue source with limited strategic value but stable cash generation.
Help build intelligence for Rivus Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rivus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE combination product; minimal strategic focus as company pivots toward proprietary metabolic platform.
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH - GlobeNewswire
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH GlobeNewswire
Sarepta CEO to step down as DM1 hits home—Chutes & Ladders - Fierce Biotech
Sarepta CEO to step down as DM1 hits home—Chutes & Ladders Fierce Biotech
Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi exec - Endpoints News
Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi exec Endpoints News
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO - Pharmaceutical Executive
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO Pharmaceutical Executive
Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer - GlobeNewswire
Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer GlobeNewswire
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo